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Objectives To examine the association between
disease activity in early rheumatoid arthritis (RA),
functional limitation and long-term orthopaedic
episodes.
Methods Health Assessment Questionnaire (HAQ)
disability scores were collected from two longitudinal
early RA inception cohorts in routine care; Early
Rheumatoid Arthritis Study and Early Rheumatoid
Arthritis Network from 1986 to 2012. The incidence of
major and intermediate orthopaedic surgical episodes
over 25 years was collected from national data sets.
Disease activity was categorised by mean disease activity
score (DAS28) annually between years 1 and 5;
remission (RDAS≤2.6), low (LDAS>2.6–3.2), low-
moderate (LMDAS≥3.2–4.19), high-moderate (HMDAS
4.2–5.1) and high (HDAS>5.1).
Results Data from 2045 patients were analysed.
Patients in RDAS showed no HAQ progression over
5 years, whereas there was a signiﬁcant relationship
between rising DAS28 category and HAQ at 1 year, and
the rate of HAQ progression between years 1 and
5. During 27 986 person-years follow-up, 392
intermediate and 591 major surgeries were observed.
Compared with the RDAS category, there was a
signiﬁcantly increased cumulative incidence of
intermediate surgery in HDAS (OR 2.59 CI 1.49 to 4.52)
and HMDAS (OR 1.8 CI 1.05 to 3.11) categories, and
for major surgery in HDAS (OR 2.48 CI 1.5 to 4.11),
HMDAS (OR 2.16 CI 1.32 to 3.52) and LMDAS (OR
2.07 CI 1.28 to 3.33) categories. There was no
signiﬁcant difference in HAQ progression or orthopaedic
episodes between RDAS and LDAS categories.
Conclusions There is an association between disease
activity and both poor function and long-term
orthopaedic episodes. This illustrates the far from benign
consequences of persistent moderate disease activity,
and supports European League Against Rheumatism
treat to target recommendations to secure low disease
activity or remission in all patients.
INTRODUCTION
Treating rheumatoid arthritis (RA) to target (T2T)
has become an internationally agreed standard of
good practice1 embodying the principle that rapid
attainment of remission, or low disease activity, can
halt joint damage and maintain good quality of life.
European League Against Rheumatism (EULAR)
guidelines for the management of RA are predi-
cated on the T2T principle, and recommend use of
both conventional synthetic disease modifying anti-
rheumatic drugs (csDMARDs) and biologics
DMARD (bDMARD) to achieve this. Some coun-
tries and healthcare systems restrict use of
bDMARDs to patients with a persistent disease
activity score (DAS28) of 5.1 or more,2 3 well
above the highest suggested T2T DAS28 of 3.2.1
We have previously reported a low likelihood of
achieving low DAS (LDAS) in patients with RA
with a DAS28 score in the moderate range, 3.2–5.1
(mDAS), using csDMARD therapies in a real world
setting. In patients with mDAS at year 1, only 27%
achieved LDAS at year 2. In those with a year 1
DAS28 of 4.2–5.1, even less achieved LDAS at year
2 and year 3, 16% and 19%, respectively.4 The
conclusion is that patients with RA with mDAS at
year 1 are unlikely to achieve the least demanding
T2T standard of LDAS with continued csDMARDs
alone. These ﬁndings have been supported by other
studies with high remission rates observed in
patients with moderate disease starting biologics.5–7
Similarly, longitudinal relationships between mDAS
and functional disability have been reported.7 8
However, there remains an important gap in the lit-
erature on long-term outcomes of mDAS, particu-
larly surrogate markers of joint destruction such as
orthopaedic surgery.
The objectives of this study were to examine
associations between disease activity during years
1–5 after ﬁrst presentation with (i) functional
outcome, measured using Health Assessment
Questionnaire (HAQ), over the same period, and
(ii) orthopaedic interventions over a period of up
to 25 years after presentation.
METHODS
Patient databases
The Early Rheumatoid Arthritis Study (ERAS) is a
multicentre inception cohort which recruited 1465
patients with early RA (<2 years disease duration,
no prior csDMARD) between 1986 and 1999 from
nine hospitals in England, followed yearly for up to
25 years (median follow-up 10 years). The Early
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RA Network (ERAN) has similar design and recruited 1236
early RA patients (<3 years disease duration) from 23 centres in
England, Wales and Ireland between 2002–2012 with a median
follow-up of 6 years. Recruitment was based on clinician diag-
nosis with 70% of patients fulﬁlling the minimum American
Rheumatism Association (ARA) criteria9 for RA at baseline and
96% by last visit.
Clinical, laboratory and functional measures
Clinical, laboratory and functional features, including rheumatoid
factor (RF) status, radiographs of hand/feet and treatment, were
recorded in both cohorts at baseline, between 3/6 and 12 months,
then yearly on standardised case report forms (CRFs).4 10 Disease
activity was calculated according to the original three variable
methods in ERAS (DAS)11 12 and the more recent four variable
DAS2812–14 in ERAN, compatibility achieved with a transform-
ation formula.15 HAQ was recorded at every patient visit.16
Information on anti-citrullinated peptide antibody (ACPA) posi-
tivity was available for a limited number in ERAN only.
DAS28 severity over time
For the purpose of this study, disease severity over time was
deﬁned using the mean of all DAS28 recordings between years 1
and 5. Baseline and 3–6 month assessments were excluded due to
the prevalence of non-treatment with csDMARDs at those visits.
Nearly all patients had commenced csDMARDs by 1 year
(ERAS=95.8%; ERAN=99.8%). Since there are a limited number
of observations with equal time intervals, the mean DAS28 over
time provides data that are equivalent to the area under the curve
method of quantifying dosage. As such, the mean DAS28 can be
considered as the average yearly disease activity ‘dose’ while
treated. For analysis the mean year 1– 5 DAS28 score for each
patient was allocated into one of the following ﬁve categories:
remission (RDAS≤2.6), low (LDAS>2.6–3.2), low-moderate
(LMDAS≥3.2–4.19), high-moderate (HMDAS 4.2–5.1) or high
DAS (HDAS>5.1). The mDAS category was split into two levels
based on earlier ﬁndings in ERAN of differences in outcomes
between these groups.4
Treatment proﬁles
Patients were treated according to usual care in all centres,
without speciﬁc protocols, T2T or other external inﬂuences. In
ERAS, csDMARD use was mainly sequential monotherapy.17 In
ERAN, more frequent and earlier use of combination
csDMARD therapies and in a small proportion bDMARDs
(<2% by 1 year, <10% by 3 years) were employed.18 Median
time from symptom onset to ﬁrst rheumatology outpatient visit
was 6 months in both cohorts and time to ﬁrst csDMARD initi-
ation 1 (ERAN) to 2 (ERAS) months later.
Orthopaedic data and linkage with national data sets
Orthopaedic data from CRFs and two national data sets were
merged as previously described.19 Hospital Episode Statistics
records inpatient and outpatient orthopaedic interventions
undertaken at National Health Service (NHS) hospitals in
England. The National Joint Registry records hip, knee and
ankle arthroplasty (more recently elbow and shoulder) under-
taken in the NHS and independent healthcare sectors.
Orthopaedic interventions were categorised by joint type and
procedure:19 (1) ‘major’ representing large joint arthroplasty (ie,
hips, knees, shoulders and elbows) and surgery to the cervical
spine; (2) ‘intermediate’ representing mainly wrist, hand and
hind/forefoot reconstructive procedures (eg, arthroplasty, syno-
vectomy and arthrodesis).
Statistical analysis
Summary statistics were used to describe demographic and base-
line data between the mean DAS28 groups. HAQ progression
between years 1 and 5 was estimated using linear mixed effects
modelling incorporating a within-individual random intercept
and a random slope for time. Individual HAQ scores at each
assessment between 1 and 5 years were included as outcome
variables. Time in years was included as a continuous variable
(with random slope) allowing for the interpretation as the linear
yearly change in HAQ (annualised progression) between 1 and
5 years. Preliminary analysis conﬁrmed that a linear change over
time provided acceptable explanatory ﬁt, compared with a
quadratic trend with acceleration of the progression rate.
DAS28 category was included as dummy coded variables with
an interaction term with time. This allows for the estimation of
HAQ at 1 year and the rate of HAQ progression for each
DAS28 category, accounting for the repeated measurement of
HAQ within individuals.i To protect against confounding, the
HAQ progression analysis controlled for age at RA onset,
gender, baseline RF, erosions, calendar year of ﬁrst visit, current
treatment using dummy coded variables for csDMARD,
bDMARDs and steroid prescription in the previous year. To
avoid confounding by orthopaedic surgery, HAQ scores mea-
sured at time points following surgery were omitted. SEs were
estimated using 1000 bootstrap resamples. Tests for differences
in HAQ at 1 year and rate of progression between DAS28 cat-
egories were corrected for multiple testing using the Bonferroni
method (critical z value 2.87, 5% α). Additional analyses, to
further probe the association between DAS28 and HAQ,
included mean 1–5 year DAS28 as a continuous variable and,
separately, individual DAS28 scores as time-dependent variables.
Time in months to ﬁrst intermediate or major orthopaedic
intervention was estimated using multivariate competing risks
regression models with censoring at April 2011 (latest date for
linkage to national data sets) with death included as a competing
risk. For individuals where linkage to national data sets was not
possible (eg, died before 1998) censoring was at last visit. As
with the HAQ progression analysis, DAS28 categories were
included as dummy coded variables, and the analysis protected
against confounding by controlling for age at RA onset, gender
and baseline HAQ, RF, erosions and calendar year of ﬁrst visit.6
Again, additional analysis included mean DAS28 as a continuous
variable. All analyses were carried out in Stata V.14.0.
RESULTS
Disease activity categories
A total of 2045 (76%) patients had DAS28 recorded at least
twice between years 1 and 5. The mean number of DAS28 obser-
vations between 1 and 5 years was 3.5 out of 5 possible assess-
ments, and between baseline to 5 years was 5.6 out of 7 possible
assessments. Of these, using the mean DAS28 score over time,
21% were in the RDAS category, 15% in the LDAS, 26% in the
LMDAS, 21% in the HMDAS and 18% in the HDAS category.
The majority of patients were observed to have DAS28 scores
within the mean DAS28 category to which they were assigned on
the majority of occasions (ﬁgure 1). Only 16.4% of patients had
more than half of their observations outside the range of their
allocated mean DAS28 category, and 6.7% had no observations
within their assigned category. The mean within-person SD for
DAS28 between years 1 and 5 was 0.84. Table 1 summarises
iIn additional post-hoc analyses, RF or erosion status displayed negligible
effect modulation.
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patient demographics, disease measures at the time of recruit-
ment to the ERAS/ERAN cohort, csDMARD use and ortho-
paedic surgery by DAS28 category. Nearly all patients who were
prescribed csDMARDs had started treatment by the 1-year
assessment (ERAS=95.8%; ERAN=99.8%).
Disease activity and HAQ progression up to year 5
Figure 2 shows the HAQ trajectories for each of the ﬁve mean
DAS28 categories. There is a clear relationship between DAS28
category and HAQ at year 1 (χ2(4)=682.9, p<0.001) and HAQ
progression between years 1 and 5 (χ2(4)=51.7, p<0.001).
At year 1, HAQ was statistically signiﬁcantly higher for each
DAS28 category compared with the RDAS category and, due to
greater progression, was further exaggerated by year 5 (all
Bonferroni-corrected contrasts p<0.05). For the remission cat-
egory HAQ at year 1 was 0.304 (95% CI 0.245 to 0.363) and
did not increase signiﬁcantly with time (annualised progres-
sion=−0.008; p=0.345; 95% CI −0.025 to 0.009). The LDAS
category had a higher HAQ at year 1 (0.522; 95% CI 0.455 to
0.589) and experienced slow but signiﬁcant progression over
time (0.023; p=0.020; 95% CI 0.004 to 0.044). The LMDAS
and HMDAS categories differed in terms of HAQ at year 1
(0.753; 95% CI 0.703 to 0.803 vs 1.097; 95% CI 1.041 to
1.153, respectively) and both progressed signiﬁcantly and simi-
larly over time (0.047; p<0.001; 95% CI 0.033 to 0.062 and
0.049; p<0.001; 95% CI 0.032 to 0.066, respectively). The
HDAS category had the highest HAQ at year 1 (1.555; 95% CI
1.494 to 1.616) and experienced the most rapid rate of
Figure 1 Disease activity score
(DAS28) scores from year 1 to 5 by
disease activity category.
Table 1 Patient demographic, disease measures, csDMARD use and orthopaedic surgery by DAS28 category
DAS28 categories
Remission Low Low-moderate High-moderate High
Total n (%) 425 (21) 301 (15) 524 (26) 426 (21) 369 (18)
Females (%) 52 57 69 77 82
Age RA onset
(mean, SD)
53.4, 14.0 55.5, 13.9 55.8, 13.6 55.7, 14.5 56.5, 13.6
Baseline ESR mm/h
(median, IQR)
20, 32 28, 34 33, 43 37, 42 42, 40
Baseline Hb
(mean, SD)
13.1, 1.45 13.1, 1.51 12.9, 1.50 12.6, 1.60 12.4, 1.54
Baseline DAS28
(mean, SD)
4.00, 1.42 4.47, 1.27 4.76, 1.21 5.32, 1.16 5.82, 1.05
Baseline HAQ
(mean, SD)
0.81, 0.70 0.91, 0.70 1.07, 0.71 1.29, 0.71 1.59, 0.73
Baseline BMI
(median, IQR)
25, 5.28 25, 4.87 26, 6.24 26, 6.58 26, 6.20
csDMARDs by 1 year
(n, %)
369, 86.8 251, 83.4 471, 89.9 396, 93.0 356, 96.5
csDMARDs weeks to start
(median, IQR)
2, 0–6 2, 0–13 2, 0–9 2, 0–6 2, 0–6
bDMARDs by 1 year
(n, %)
6, 1.4 1, 0.3 3, 0.6 1, 0.2 4, 1.1
BMI, body mass index; DAS, disease activity score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; csDMARDs, conventional synthetic disease modifying
antirheumatic drugs; Hb, haemoglobin; RA, rheumatoid arthritis; bDMARDs, biologics DMARD.
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progression (0.078; p<0.001; 95% CI 0.060 to 0.097).
Compared with the RDAS category HAQ progressed at a signiﬁ-
cantly faster rate in all other DAS28 categories, though follow-
ing Bonferroni correction only the rates for the LMDAS,
HMDAS and HDAS categories were signiﬁcant. Compared with
the LDAS category only the HDAS category progressed at a sig-
niﬁcantly faster rate (Bonferroni-corrected contrast p<0.05).
Analysis with mean DAS between 1 and 5 years as a continu-
ous variable indicated that each one unit increase in mean
DAS28 score was associated with a 0.193 (95% CI 0.178 to
0.208; p<0.001) higher HAQ score at 1 year, and an annual
HAQ progression rate that is increased by 0.005 (95% CI 0.001
to 0.010; p=0.023). Further analysis, including individual DAS
scores at each assessment as a time-dependent variable gave
similar results, although the impact of DAS28 on annualised
HAQ progression was enhanced. Each one unit increase in
DAS28 score at the same assessment as HAQ was associated
with a 0.176 (95% CI 0.178 to 0.208; p<0.001) higher HAQ
score at 1 year, and an annual HAQ progression rate that is
increased by 0.013 (95% CI 0.008 to 0.170; p<0.001).
Sensitivity analysis (data not shown) indicated the same pattern
of association between DAS28 category and HAQ between the
ERAS and ERAN cohorts. Within each DAS28 category none of
the rates of HAQ progression differed signiﬁcantly between
ERAS and ERAN. A further sensitivity analysis excluded patients
with >50% of their scores outside of the DAS28 category to
which they were assigned. The estimates of HAQ progression
did not differ between DAS28 categories, though CIs were
wider due to loss of precision.
Disease activity and prediction of orthopaedic surgery
During 27 986 person-years follow-up, a total of 392 intermedi-
ate and 591 major surgeries were observed. This translates to a
crude incidence rate of 14.0 (95% CI 12.7 to 15.5) per 1000
person-years and 21.1 (95% CI 19.4 to 22.9) per 1000 person-
years, respectively. The 10-year cumulative incidence of inter-
mediate surgery was 8.3% (95% CI 7.1% to 9.7%) and major
surgery 11.7% (95% CI 10.4% to 13.4%). Figures 3 and 4
show intermediate and major surgery cumulative incidence,
respectively, in each of the DAS28 categories up to 25 years esti-
mated from multivariate competing risks regression models. An
increasing risk for both intermediate and major surgery was
seen moving from low to moderate to high DAS28 categories
(table 2).
Compared with patients in the RDAS category, there was a
signiﬁcantly increased cumulative incidence of intermediate
surgery observed in patients in the HMDAS (HR 1.8; 95% CI
1.05 to 3.11) and HDAS (HR 2.59; 95% CI 1.49 to 4.52) cat-
egories, and for major surgery a signiﬁcantly increased cumula-
tive incidence in patients in the HDAS (HR 2.48; 95% CI 1.5
to 4.11), HMDAS (HR 2.16; 95% CI 1.32 to 3.52) and
LMDAS (HR 2.07; 95% CI 1.28 to –3.33) categories (table 2).
Comparing the LDAS with the RDAS category, the HR for
major and intermediate surgery was 1.65 and 1.13, respectively,
but no statistical signiﬁcance was reached (p>0.05).
Further analysis including DAS as a continuous, rather than
categorical, variable also supported the relationship between
disease activity and increased risk of both intermediate (HR
1.31; 95% CI 1.15 to 1.48) and major surgery (HR 1.22; 95%
CI 1.10 to 1.36).
A sensitivity analysis was performed with the analysis con-
ducted separately for each cohort (data not shown). The same
increasing trend in HR was observed for increasing DAS28 cat-
egory with no substantive difference in the estimates between
cohorts. A further sensitivity analysis excluded patients with
>50% of their scores outside of the DAS category to which
they were assigned. The HR estimates for each DAS28 category
did not differ substantively compared with the original analysis.
Figure 2 Health Assessment Questionnaire (HAQ) progression by
disease activity score (DAS28) category. Shaded areas indicate 95% CIs.
Figure 3 Cumulative incidence for intermediate orthopaedic surgery
by disease activity score (DAS28) category over time.
Figure 4 Cumulative incidence for major orthopaedic surgery by
disease activity score (DAS28) category over time.
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DISCUSSION
This study reports on functional and orthopaedic surgery out-
comes in two large RA inception cohorts, both surrogate
markers for failed medical management.20–23 Our ﬁndings dem-
onstrate an association between increasing disease activity, mea-
sured by mean DAS28 after csDMARD initiation, and
functional limitation, measured by absolute HAQ scores and the
rate of progression of HAQ over 5 years. Patients in the RDAS
category had no HAQ progression, demonstrating that func-
tional preservation is achievable; as embodied in the T2T princi-
ples.1 While predictably patients in the HDAS category showed
the highest functional limitation and progression, those in the
LMDAS and HMDAS categories also demonstrated signiﬁcantly
greater progression than the RDAS category, illustrating that
these are not benign states.
The orthopaedic data support these ﬁndings, demonstrating
that the cumulative incidence of intermediate and major surgery
over 25 years is associated with disease activity between years 1
and 5. In particular, patients in the LMDAS and HMDAS cat-
egories had a signiﬁcantly higher prevalence of major surgery
compared with those in RDAS and this was also true for inter-
mediate surgery for those in HMDAS, illustrating the far from
benign consequences of sustained mDAS and csDMARD
therapy between years 1 and 5. These ﬁndings highlight the
long-term health burden in patients with RA not achieving early
and sustained remission.
Our results are supported by data from the Evaluation et
Suivi de POlyarthrites Indifférenciées Récentes (ESPOIR)
cohort8 where patients with early RA and persistent mDAS
demonstrated adverse outcomes, compared with those in sus-
tained remission during the ﬁrst year; evidenced by increased
3-year radiographic progression, increased Health Assessment
Questionnaire Disability Index (HAQ-DI) at 3 and 5 years and a
ﬁvefold increase in missed workdays over 5 years.
The observations made in our study have critical implications
in countries like England and Wales where eligibility criteria to
commence bDMARDs are based on DAS28 thresholds which
exclude moderate disease.2 This applies to as many as 47% of
patients in ERAS/ERAN who were categorised in the mDAS
range between years 1 and 5, and would not be permitted to
bDMARDs by The National Institute for Health and Care
Excellence (NICE). In contrast, Swedish data report that half
of all ﬁrst time tumour necrosis factor (TNF) inhibitor starters
in 2011 had a DAS28 of <5.2.24 Furthermore, data from the
Antirheumatic Therapies In Sweden (ARTIS) register demon-
strate the cost-effectiveness of bDMARDs in patients with
mDAS and HDAS.25 Others have demonstrated the clinical
beneﬁts of starting bDMARDs earlier and at lower disease
activity levels including mDAS.7 26 It is therefore evident that
bDMARDs are effective when used as part of a T2T strategy.1
In contrast, our data reveal the adverse consequences when
restrictive healthcare systems deny patients with mDAS such
therapies.
Intriguingly, when comparing the LDAS and RDAS categories,
similar functional and orthopaedic outcomes were seen. The
annual rate of HAQ progression in the general population aged
over 50 has been reported to be 0.01.27 Our ﬁndings for the
RDAS (−0.008) and LDAS (0.023) groups between years 1 and
5 are not signiﬁcantly different from this, nor from each other.
In terms of orthopaedic episodes, the differences observed
between the LDAS and RDAS categories for intermediate and
major surgery were also not statistically signiﬁcant. This
prompts the question, whether in a T2T strategy it is necessary
to reduce disease activity as low as remission, or alternatively
whether LDAS is sufﬁcient. Our data would seem to support
the EULAR recommendation that LDAS is an acceptable target
in patients with established disease.1
The real-life setting, large patient numbers and long follow-up
are strengths that have enabled an analysis of the consequences of
a range of disease activity states in the ﬁrst 5 years on function
and orthopaedic episodes up to 25 years later. The linkage with
national data sets and high follow-up rates add to the validity and
accuracy of data examined. HAQ is recognised as a predictor of
key outcomes of disease such as mortality,28–30 work disability31–
33 and healthcare resource utilisation34 and is therefore a power-
ful outcome measure. This analysis controlled for key parameters
of disease which could have inﬂuenced the results including year
of ﬁrst visit (as an indirect measure of treatment strategies
employed at different times), treatment using dummy coded vari-
ables for csDMARDs, and bDMARDs, and steroid prescription
in the previous year. However, the approach used does not fully
account for confounding by indication, therefore it is not pos-
sible to make speciﬁc causal inferences about the impact of differ-
ent treatment regimens on outcome.35
In our analysis, allocation of patients into one of ﬁve DAS28
categories as an indicator of disease severity over time was based
on the mean DAS28 score between years 1 and 5. This represents
average disease activity per patient but does not imply that
patients will have spent all of the study period persistently in the
DAS28 category to which they were allocated, nor indeed that
there is no ﬂuctuation in DAS28 scores over time. Findings for
the mean DAS28 groupings should be considered in terms of the
annual ‘dose’ of DAS28, while on treatment. Nevertheless, as
only 16.4% of patients (ﬁgure 1) had more than half of their
observations outside the range of their category, for many the
allocated DAS category indicates a relatively persistent state. This
reﬂects the inability of standard care at that time (largely in the
absence of bDMARDs), to achieve contemporary T2Toutcomes.
A limitation is that, though DAS28 and HAQ data were available
beyond 5 years for both cohorts, the number of ERAN patients
who provided data beyond 5 years was limited due to recent
recruitment. Restricting the analysis to the ﬁrst 5 years, during
which the disease progresses from early to established, increases
likely generalisability to modern patients treated with
csDMARDs. This study illustrates an association between disease
activity and both progression of functional limitation and
Table 2 HRs (95% CI) for intermediate and major orthopaedic surgery by DAS28 category
DAS28 category
Remission† Low Low-moderate High-moderate High
Intermediate surgery 1.00 1.13 (0.60 to 2.11) 1.33 (0.77 to 2.29) 1.80* (1.05 to 3.11) 2.59* (1.49 to 4.52)
Major surgery 1.00 1.65 (0.97 to 2.80) 2.07** (1.28 to 3.33) 2.16** (1.32 to 3.52) 2.48** (1.50 to 4.11)
*p<0.001; **p<0.05.
†Reference category against which other DAS28 categories are compared.
DAS, disease activity score.
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orthopaedic episodes in RA, with incremental differences appar-
ent in all DAS28 categories, compared with RDAS. This supports
the selection of a DAS28 score not higher than 3.2 as a T2T
outcome, and in our opinion provides a strong argument for max-
imising treatment interventions when this has not been achieved.
Our data may be used to inform guidelines and recommendations
for the use of more intensive therapies including bDMARDs in
patients with RA with persistent mDAS. We hope this will trans-
late into a more harmonised approach to the management of RA
across the globe with fresh imperatives to adopt T2T strategies to
achieve remission or LDAS for the majority of patients.
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